ANN ARBOR, Mich., Aug. 29 /PRNewswire-FirstCall/ -- Esperion Therapeutics,
Inc. (Nasdaq: ESPR), a biopharmaceutical company dedicated to the discovery,
development and commercialization of therapies to improve the treatment of
cardiovascular disease, today announced that President and Chief Executive
Officer Roger S. Newton, Ph.D. will present at the NewsMakers in the Biotech
Industry Conference taking place on Thursday, September 4, 2003 in New York
City. Dr. Newton is scheduled to speak at 3:50 p.m. (EDT). Investors and
others may access a live audio webcast of the presentation through Esperion's
website, http://www.esperion.com , under Investor Relations / Calendar. An
audio replay of the webcast will be available on Esperion's website under
Investor Relations / Audio/Visual Archives for 14 days following the
presentation.
Esperion Therapeutics
Esperion Therapeutics, Inc. discovers and develops pharmaceutical products
for the treatment of cardiovascular disease. Esperion intends to
commercialize a novel class of drugs that focuses on a new treatment approach
called "HDL Therapy," which is based on the Company's understanding of high-
density lipoprotein, or HDL, function. HDL is the primary facilitator of the
reverse lipid transport, or RLT, pathway by which excess cholesterol and other
lipids are removed from artery walls and other tissues and are transported to
the liver for elimination from the body. Esperion's goal is to develop drugs
that exploit the beneficial functions of HDL within the RLT pathway. Esperion
currently has product candidates under development for the treatment of
cardiovascular disease. Esperion is listed on the Nasdaq National Market
under the symbol "ESPR."
Company Amy Cannon
Contact: Manager, Corporate Communications
Esperion Therapeutics, Inc.
(734) 222-1801
acannon@esperion.com
SOURCE Esperion Therapeutics, Inc.
 back to top
Related links:
http://www.esperion.com
CONTACT:
Amy Cannon, Manager, Corporate Communications
of Esperion Therapeutics, Inc., +1-734-222-1801,
acannon@esperion.com
|
